Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

13.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.3K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

2.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
2.1K
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

84
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
84
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.6K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.6K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

72
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72
The Two-State Receptor Model01:29

The Two-State Receptor Model

3.5K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood proteomics of paediatric bronchiolitis obliterans syndrome after haematopoietic cell transplant.

ERJ open research·2026
Same author

A lipid-immune network signature defines susceptibility to asparaginase-associated pancreatitis.

JCI insight·2026
Same author

Esomeprazole inhibits proliferation of scleroderma fibroblasts via cell cycle regulation.

Frontiers in pharmacology·2026
Same author

PLK1 inhibition by volasertib suppresses key transcriptional regulators underlying fibroblast activation and pulmonary fibrosis.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

Contribution of leukocyte telomere length to cardiovascular disease onset from genome-wide cross-trait analysis.

Nature communications·2025
Same author

From Gene Networks to Therapeutics: A Causal Inference and Deep Learning Approach for Drug Discovery.

Pharmaceuticals (Basel, Switzerland)·2025
Same journal

LabSage: Structural-Semantic Decoupling for Enhanced Retrieval-Augmented Generation in Clinical Laboratories.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

Evaluating Representation Embeddings from LLMs and Time-Series Foundation Models for Wearable Accelerometer-Based Health Prediction.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

ClinNoteAgents: An LLM Multi-Agent System for Predicting and Interpreting Heart Failure 30-Day Readmission from Clinical Notes.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

Mapping the Storm: Linking Tornado Paths to Emergency Room Surges Through Geocoded Patient Data.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

Multi-Modal Deep Learning-Based Model to Predict Burkitt Lymphoma Recurrence.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

A Multi-Model LLM Consensus Framework to Identify EHR-Predictable Eligibility Criteria in NSCLC Immunotherapy Trials.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
See all related articles

Related Experiment Video

Updated: Apr 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K

Concept Modeling-based Drug Repositioning.

Jagadeesh Patchala1, Anil G Jegga2

  • 1Department of Computer Science, University of Cincinnati, Cincinnati, Ohio, USA.

AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science
|August 26, 2015
PubMed
Summary
This summary is machine-generated.

This study proposes a novel method to discover drug repositioning opportunities by analyzing shared biomedical concepts between drugs and diseases. The approach successfully identifies potential new uses for existing medications, particularly for rare disorders.

More Related Videos

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

2.0K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Related Experiment Videos

Last Updated: Apr 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

2.0K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Area of Science:

  • Biomedical Informatics
  • Pharmacology
  • Computational Biology

Background:

  • Identifying new therapeutic uses for existing drugs (drug repositioning) is crucial for efficient drug development.
  • Existing methods often rely on serendipitous discoveries or limited data sources.

Purpose of the Study:

  • To develop and validate a computational model for identifying drug repositioning opportunities.
  • To leverage shared biomedical and genomic concepts between drugs and diseases for relationship discovery.

Main Methods:

  • Constructed a probabilistic topic model using Unified Medical Language System (UMLS) concepts from MEDLINE abstracts.
  • Quantified drug-disease similarity based on shared concept incidence.
  • Evaluated model performance using known repositioned drugs and their indications.

Main Results:

  • The probabilistic topic model effectively measures drug-disease similarity.
  • The model successfully ranked known repositioned drugs based on their similarity to original and new indications.
  • The approach facilitated the discovery of potential drug repositioning candidates for rare disorders.

Conclusions:

  • Shared biomedical concepts can predict drug-disease relationships and identify repositioning opportunities.
  • This systematic approach enables "systematically serendipitous" discovery of novel drug-disease connections.
  • The model shows promise for accelerating the identification of new therapeutic uses for existing drugs, especially for rare diseases.